Paul Krestik, DPM
Podiatrist · London, KYNPI 1588791719
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $395 of the $488 with a category attached, or 80.9%. 10 manufacturers reported payments, led by Mimedx Group, Inc. at 34.7% of the total.
Across 17 payments — averaging $28.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Mimedx Group, Inc.$169
- Stryker$121
- AbbVie$64
- Bioventus LLC$33
- Merck$26
- Organogenesis Inc.$21
- plus $54 from 4 others
What the payments were for
- Food & beverage$39581%
- Gifts$9319%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Mimedx Group, Inc. | 2 | $169 |
| Stryker | 2 | $121 |
| AbbVie | 4 | $64 |
| Bioventus LLC | 2 | $33 |
| Merck | 2 | $26 |
| Organogenesis Inc. | 1 | $21 |
| Convatec Inc. | 1 | $16 |
| Orthofix Medical, Inc. | 1 | $16 |
| Amgen | 1 | $15 |
| Aroa Biosurgery Incorporated | 1 | $7 |
How this compares
$488 in reported general payments places this provider in the 55th percentile of 54 podiatrist providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ammonium Lactate | 658 | $13,280 |
| Gabapentin | 688 | $7,932 |
| Pregabalin | 135 | $6,263 |
| Diclofenac Sodium | 148 | $4,066 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 35 | $536 |
| Ciclopirox | 19 | $501 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 22 | $274 |
| Doxycycline Hyclate | 18 | $221 |
| SsdSilver Sulfadiazine | 39 | $216 |
| Methylprednisolone | 42 | $209 |
| Silver Sulfadiazine | 32 | $208 |
| Terbinafine Hcl | 38 | $202 |
| Meloxicam | 74 | $184 |
| Ibuprofen | 34 | $168 |
| Tramadol Hcl | 11 | $95 |
Paid to pharmacies, not to this prescriber.
Other podiatrist in London
- Thomas ChildressLouisville$283K
- Joshua CogerLouisville$132K
- David SmithHopkinsville$66K
- Matthew FeltnerCampbellsville$38K
- Zachery WeyandtLouisville$37K
- Robert HerbstFlorence$24K
- Michael AllenLexington$24K
- Thomas PoynterDanville$20K
- Andrew BouwkampLouisville$19K
- Braxton RiderLouisville$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.